Trial Profile
Thorough QT Study to Evaluate the Effects of BI 207127 (Deleobuvir) Combined With Faldaprevir on Cardiac Safety Parameters in Healthy Female and Male Subjects. Randomised, Placebo Controlled, Single-blind, Three-period Crossover Phase-I-study With Moxifloxacin as Positive Control
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 Apr 2016
Price :
$35
*
At a glance
- Drugs Deleobuvir (Primary) ; Faldaprevir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 22 Jan 2014 According to ClinicalTrials.gov record, the status changed from active no longer recruiting to completed.
- 26 Oct 2013 New trial record